Skip to Main Content

Rise and shine, another busy day is on the way. The events on this side of the pond, in fact, guarantee today will be rather hectic. Better than being bored, yes? So time to get cracking. The official mascot is snoozing in a corner, the short person is hunched over a laptop and the coffee kettle is whistling away. All of which makes it possible to provide the tidbits listed below. We hope your day is productive and you remain upbeat. Look on the sunny side, as they say. Stay safe, meanwhile, and wear a mask. …

The University of Oxford hopes to present late-stage trial results on its Covid-19 vaccine candidate this year, raising hopes that the U.K. could start to roll out a successful vaccine in late December or early 2021, Reuters tells us. Oxford Vaccine Trial Chief Investigator Andrew Pollard told U.K. lawmakers that determining whether or not the vaccine worked would likely come this year, after which the data would have to be carefully reviewed by regulators and then a political decision made on who should get the vaccine.


What a difference a year — and a pandemic — make. Today, Novavax (NVAX) is slated to receive up to $2 billion from the U.S. government and a nonprofit organization to develop and manufacture a Covid-19 vaccine. But as Science explains, 18 months ago, the company faced an existential threat: delisting by the NASDAQ stock index. Following a second failed vaccine trial in less than three years, its stock plunged to less than $1 for 30 straight days. Frantic to conserve cash, Novavax sold its two manufacturing facilities and cut payroll to only 166 people.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!